Pulnovo Medical announced today that it enrolled the first two patients in a clinical study evaluating its pulmonary artery denervation (PADN) treatment.
The company’s PADN treatment utilizes a multi-pole pulmonary artery radiofrequency (RF) ablation catheter and RF ablation generator. It aims to treat pulmonary hypertension associated with left heart disease.
Pulnovo’s enrollments took place at Centro Hospitalar Universitário de Lisboa Central – Hospital de Santa Marta in Portugal. It marked the beginning of Pulnovo’s product deployment on a global scale, according to a news release.
Dr. Ruben Ramos and his team, under the guidance of Dr. Hang Zhang, performed the PADN procedure on two patients. Shanghai-based Pulnovo reported a smooth procedure with easy-to-operate devices and “excellent” results. The doctors highlighted the treatment’s safety and efficacy, as well as high-precision algorithm control. This provided stable energy output and effective surgical results.
“The PADN global multicenter clinical study is one of our key projects dedicated to innovative treatment technologies in the cardiovascular field. As an emerging treatment, PADN has enormous potential and prospects,” said Pulnovo CEO Jessie Lian. “The post-operative results of the first overseas application of PADN reflect the academic borderlessness of the moment. In the future, we will continue to firmly advance our global business, steadily promoting the teaching and learning of PADN technology. “
